Case Study: Eli Lilly accelerates impurity identification with ACD/Labs

Eli Lilly and Company - Customer Case Study

Eli Lilly and Company, a pharmaceutical firm, needed a more effective way to identify and characterize drug impurities to meet strict regulatory guidelines, which required collaboration across multiple chemistry functions. Their challenge was to streamline a complex, often manual process involving analytical data from various instruments to accelerate development and ensure patient safety. They turned to vendor ACD/Labs for its specialized software solutions.

The solution from ACD/Labs provided a unified software platform that integrated data from instruments like NMR and MS, automating data processing, peak tracking, and structure elucidation. This improved collaboration between departments, streamlined reporting, and created a searchable knowledge base of 'live' data. The results included an over 80% reduction in experiment cycle time for method development, a significant boost in scientist productivity, and the creation of a robust audit trail for regulatory compliance.

Eli Lilly and Company

John Stafford

Research Scientist, Small Molecule Design and Development